U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C25H35NO5
Molecular Weight 429.5501
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEBEVERINE

SMILES

CCN(CCCCOC(=O)c1ccc(c(c1)OC)OC)C(C)Cc2ccc(cc2)OC

InChI

InChIKey=VYVKHNNGDFVQGA-UHFFFAOYSA-N
InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3

HIDE SMILES / InChI

Description
Curator's Comment:: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021

Mebeverine is an antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract. The exact mechanism of action is not known, but multiple mechanisms, such as a decrease in ion channel permeabilities, blockade of noradrenaline reuptake, a local anesthetic effects, as well as weak anti-muscarinic and phosphodiesterase inhibitory effect might contribute to the local effects of Mebeverine. This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Most people will not have problems with Mebeverine, but some may get some side effects, such as: difficulty in breathing, swelling of face, neck, tongue or throat, skin rash, red itchy skin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Alpha-1 adrenergic receptor (guinea pig)
Target ID: Muscarinic acetylcholine receptors (guinea pig)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Colofac

Approved Use

Colofac is used to treat symptoms of irritable bowel syndrome and similar problems.

Launch Date

258595200000
Palliative
Colofac

Approved Use

This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis.

Launch Date

258595200000
Palliative
Colofac

Approved Use

This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis

Launch Date

258595200000
PubMed

PubMed

TitleDatePubMed
Rapid accurate mass desorption electrospray ionisation tandem mass spectrometry of pharmaceutical samples.
2005
A new RP-HPLC method for analysis of mebeverine hydrochloride in raw materials and tablets.
2005 Apr
[Mebeverine for complex treatment of opisthorchiasis].
2006
[The pain problem as a historic aspect. Pain at the biliary pathology. Mebeverine hydrochloride as a part of complex therapy].
2006
Generic and brand-name drugs. Are different criteria sufficiently taken into account before granting market authorisation?
2006
Formulation of an antispasmodic drug as a topical local anesthetic.
2006 Dec 1
Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial.
2006 Jun
Investigative implications of the instability and metabolism of mebeverine.
2006 Mar
Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases.
2006 May
"My patients are the sickest".
2006 May
Mebeverine influences sodium ion transport in the distal colon.
2006 Sep-Oct
[Chronic abdominal pain syndrome in biliary pathology].
2007
[Assessment of the efficacy of mebeverine in the complex therapy of chronic noncalculolis cholecystitis and biliary dysfunction].
2007
Colon-specific drug delivery for mebeverine hydrochloride.
2007 Dec
Development of in situ ion selective sensors for dissolution.
2007 Jan 2
[Drug treatment of irritable bowel syndrome: an unmet need].
2007 Mar
Improving the detection limits of antispasmodic drugs electrodes by using modified membrane sensors with inner solid contact.
2007 May 9
A novel formulation for mebeverine hydrochloride.
2007 Oct
Health technology assessment and ill-structured problems: a case study concerning the drug mebeverine.
2007 Summer
[Efficacy of duspatalin in the treatment and prophylaxis of postcholecystectomic syndrome].
2008
Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome.
2008 Apr
Serotonin receptor modulators in the treatment of irritable bowel syndrome.
2008 Feb
Evaluation of the Birmingham IBS symptom questionnaire.
2008 Jul 23
Spectrophotometric determination of benzydamine HCl, levamisole HCl and mebeverine HCl through ion-pair complex formation with methyl orange.
2008 Mar
[Irritable bowel syndrome-an unbeloved problem].
2008 Mar 27
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
2008 May
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.
2008 Nov 13
Drug use in children: cohort study in three European countries.
2008 Nov 24
Development of membrane selective electrode for determination of the antipsychotic sulpiride in pharmaceuticals and urine.
2009
[The effectiveness of spasmolytic therapy in chronic acalculous cholecystitis].
2009
[How to raise efficacy of gastroesophageal reflux disease treatment].
2009
Psychological associations of irritable bowel syndrome besides panic disorder: an often overlooked reality.
2009
Validated LC-MS/MS method for determination of Alverine and one of its hydroxy metabolites in human plasma along with its application to a bioequivalence study.
2009 Jan 15
pH-Sensitive Mebeverine Microspheres for Colon Delivery.
2009 Jul
The four killers of Meckel's diverticulum.
2009 May
[A method for non-medicamentous treatment of irritated bowel syndrome].
2009 May-Jun
[Modern approaches to the therapy of biliary system diseases].
2010
Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care.
2010 Apr
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.
2010 Feb 7
Validated HPLC determination of the two fixed dose combinations (chlordiazepoxide hydrochloride and mebeverine hydrochloride; carvedilol and hydrochlorothiazide) in their tablets.
2010 Jul-Aug
Design and formulation of mebeverine HCl semisolid formulations for intraorally administration.
2010 Mar
Colloids as a sink for certain pharmaceuticals in the aquatic environment.
2010 May
First derivative synchronous fluorescence spectroscopy for the simultaneous determination of sulpiride and mebeverine hydrochloride in their combined tablets and application to real human plasma.
2010 Nov
Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial).
2010 Nov 18
Topical piroxicam in vitro release and in vivo anti-inflammatory and analgesic effects from palm oil esters-based nanocream.
2010 Nov 4
Development and validation of stability indicating HPLC and HPTLC methods for determination of sulpiride and mebeverine hydrochloride in combination.
2010 Sep
Autoimmune hepatitis triggered by nitrofurantoin: a case series.
2010 Sep 23
Presentations of perforated colonic pathology in patients with polymyalgia rheumatica: two case reports.
2010 Sep 6
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Sample Use Guides

One tablet (135 mg) three times a day. This may be gradually reduced after a few weeks when the desired effect has been obtained. The tablets are best taken 20 minutes before meals.
Route of Administration: Oral
In Vitro Use Guide
Mebeverine (10^5-10^4 M) suppressed the amplitude of the action potential and lengthened the time between stimulation and the top of the response in non-myelinated fibres of the vagus nerve.
Name Type Language
MEBEVERINE
INN   MI   WHO-DD  
INN  
Official Name English
MEBEVERINE [MI]
Common Name English
MEBEVERINE [WHO-DD]
Common Name English
ARLUY
Brand Name English
BENZOIC ACID, 3,4-DIMETHOXY-, 4-(ETHYL(2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)BUTYL ESTER
Common Name English
VERATRIC ACID, 4-((ETHYL(P-METHOXY-.ALPHA.-METHYLPHENETHYL))AMINO)BUTYL ESTER
Common Name English
4-(ETHYL(P-METHOXY-.ALPHA.-METHYLPHENETHYL)AMINO)BUTYL VERATRATE
Common Name English
MEBEVERINE [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66880
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
WHO-ATC A03AA04
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
WHO-VATC QA03AA04
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
Code System Code Type Description
EPA CompTox
3625-06-7
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
FDA UNII
7F80CC3NNV
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
DRUG CENTRAL
1642
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
CAS
3625-06-7
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
RXCUI
29410
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY RxNorm
PUBCHEM
4031
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
ECHA (EC/EINECS)
222-830-4
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
ChEMBL
CHEMBL282121
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
EVMPD
SUB08662MIG
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
MERCK INDEX
M7108
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY Merck Index
MESH
C005096
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
WIKIPEDIA
MEBEVERINE
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
INN
1191
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
DRUG BANK
DB12554
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
NCI_THESAURUS
C83909
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY